Swedish Orphan Biovitrum AB (SOBI) AI Stock Analysis

• Market Cap: kr92.60B
• Dividend Yield: N/A
• Average Volume (3M): 279.17K
• Price to Earnings (P/E): 21.5
• Beta (1Y): 0.98
• Revenue Growth: 13.75%
• EPS Growth: 101.18%
• Country: SE
• Employees: 1,895
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.83
• Shares Outstanding: 356,000,060
• 10 Day Avg. Volume: 273,828
• 30 Day Avg. Volume: 279,174
• PEG Ratio: 0.53
• Price to Book (P/B): 2.69
• Price to Sales (P/S): 4.17
• P/FCF Ratio: 24.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr341.00
• Price Target Upside: 24.45% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 68 Neutral
• Price Target: kr300.00 ▲(9.49% Upside)

Swedish Orphan Biovitrum AB's strong financial performance is the primary driver of its stock score, supported by robust profitability and a solid balance sheet. However, technical analysis indicates bearish momentum, which tempers the overall score. The valuation is moderate, with no dividend yield to attract income investors. The absence of recent earnings call data and corporate events means these factors do not influence the score.

Swedish Orphan Biovitrum AB Business Overview & Revenue Model

Company Description

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

How the Company Makes Money

SOBI generates revenue primarily through the sale of its specialized pharmaceuticals and therapies targeted at rare diseases. The company's key revenue streams include product sales from its hematology and immunology segments, where it offers treatments for conditions such as hemophilia and hereditary angioedema. Additionally, SOBI engages in strategic partnerships and collaborations with other pharmaceutical companies to enhance its product offerings and market reach. These partnerships often involve licensing agreements, co-development, and co-promotion arrangements that contribute to its earnings. SOBI's revenue is further supported by its investment in research and development, which enables the company to innovate and expand its portfolio of rare disease treatments.

Swedish Orphan Biovitrum AB Financial Statement Overview

Summary

Swedish Orphan Biovitrum AB shows strong financial performance with consistent revenue growth and robust profitability margins. The balance sheet is stable with a reasonable debt-to-equity ratio, and cash flows are healthy, supporting operational and investment activities.

Income Statement

Swedish Orphan Biovitrum AB shows strong financial performance with a consistent increase in revenue from 2020 to TTM (Trailing-Twelve-Months) with a notable revenue growth rate of 4.1% from the previous annual period. The company maintains robust profitability, with a gross profit margin of 74.9% and a net profit margin of 15.1% in TTM. EBIT and EBITDA margins are also healthy at 21.7% and 35.8% respectively, indicating efficient core operations and strong cash generation capabilities. Despite slight fluctuations, the upward trajectory in revenue and profitability margins reflects a well-managed income statement.

Balance Sheet

The balance sheet presents a stable financial position with total assets of 70.1 billion and stockholders' equity of 39 billion in TTM. The debt-to-equity ratio stands at a reasonable 0.36, indicating a balanced approach to leveraging. Return on equity remains strong at 10.1%, showcasing effective utilization of equity to generate profits. The equity ratio of 55.7% suggests a solid capital structure with substantial equity financing. While the company has managed debt effectively, maintaining this balance is crucial to mitigate potential risks associated with high leverage.

Cash Flow

The company's cash flow statement highlights efficient cash management. Operating cash flow to net income ratio is favorable at 1.93, indicating strong cash generation relative to net income. Free cash flow has shown significant growth of 21.5% from the previous year, reflecting the company's ability to generate cash after capital expenditures. However, the free cash flow to net income ratio stands at 1.35, suggesting room for improvement in converting earnings to cash. Overall, cash flows are robust, supporting the company's operational and investment activities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	26.97B	26.03B	22.12B	18.79B	15.53B	15.26B
Gross Profit	21.12B	20.24B	17.13B	14.01B	12.04B	12.04B
EBITDA	9.75B	9.30B	7.23B	6.05B	5.71B	6.73B
Net Income	4.37B	3.88B	2.41B	2.64B	2.68B	3.25B
Balance Sheet
Total Assets	68.75B	75.44B	74.03B	52.50B	48.66B	48.28B
Cash, Cash Equivalents and Short-Term Investments	1.06B	1.14B	904.00M	1.36B	1.04B	404.00M
Total Debt	12.81B	16.73B	20.48B	9.10B	10.91B	14.57B
Total Liabilities	29.68B	35.15B	40.16B	25.97B	25.46B	28.08B
Stockholders Equity	39.06B	40.29B	33.87B	26.52B	23.20B	20.21B
Cash Flow
Free Cash Flow	4.07B	4.38B	-473.00M	3.19B	5.10B	1.36B
Operating Cash Flow	6.74B	7.39B	4.47B	4.67B	5.47B	5.21B
Investing Cash Flow	-2.82B	-3.09B	-21.90B	-1.48B	-367.00M	-3.96B
Financing Cash Flow	-3.57B	-4.00B	17.01B	-2.99B	-4.47B	-1.57B

Swedish Orphan Biovitrum AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 274.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SOBI, the sentiment is Negative. The current price of 274 is below the 20-day moving average (MA) of 277.44, below the 50-day MA of 284.57, and below the 200-day MA of 301.74, indicating a bearish trend. The MACD of -3.71 indicates Positive momentum. The RSI at 46.29 is Neutral, neither overbought nor oversold. The STOCH value of 32.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SOBI.

Swedish Orphan Biovitrum AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAMX	77 Outperform	$38.96B	53.71	20.47%	―	42.25%	210.72%
BONEX	70 Neutral	kr20.98B	140.49	20.14%	―	44.52%	-49.29%
MCOV.B	69 Neutral	kr40.46B	83.34		0.54%	15.92%	82.51%
SOBI	68 Neutral	kr92.60B	21.51	11.60%	―	13.75%	101.18%
ALIF.B	66 Neutral	$20.52B	60.86	6.27%	0.45%	4.56%	185.59%
EKTA.B	55 Neutral	kr17.90B	75.54	2.43%	5.13%	-0.57%	-81.80%
Sector *	51 Neutral	$7.39B	0.36	-62.86%	2.36%	15.48%	-2.68%

Swedish Orphan Biovitrum AB Corporate Events

Sobi Reports Strong Q2 2025 Growth and Pipeline Progress

Sobi reported a strong second quarter in 2025, with a 22% growth at constant exchange rates, driven by significant increases in haematology and immunology revenues. Key developments include the approval of Gamifant for HLH/MAS in Still’s disease and the submission of NASP for uncontrolled gout in the US. The company’s strategic portfolio saw a 65% growth, highlighting its commitment to rare diseases and strong commercial execution. Despite some challenges with Vonjo, Sobi remains focused on expanding its use and advancing its pipeline, supported by organizational restructuring to enhance support for upcoming launches.

The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK350.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.

Sobi Board Approves Share Repurchase for Incentive Program

Swedish Orphan Biovitrum AB’s Board of Directors has decided to repurchase class C shares to fulfill commitments under its long-term incentive programs. This move, authorized by the Annual General Meeting, aims to convert these shares into common shares, increasing the total number of common shares held by the company.

The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK350.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.

Sobi and Apellis Amend Royalty Agreement for Aspaveli

Sobi has entered into a capped royalty purchase agreement with Apellis Pharmaceuticals, significantly reducing its ex-U.S. royalty obligations for Aspaveli in exchange for a $275 million upfront payment and potential milestone payments. This strategic move underscores Sobi’s commitment to advancing treatments for rare diseases, particularly C3G and IC-MPGN, and highlights the potential of Aspaveli to transform patient outcomes in these areas.

The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK350.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.

Sobi’s Gamifant Receives FDA Approval for Treating MAS in Still’s Disease

Swedish Orphan Biovitrum AB (Sobi) announced the FDA approval of Gamifant (emapalumab-lzsg) as the first treatment for adults and children with Macrophage Activation Syndrome (MAS) in Still’s disease. This approval, based on pivotal studies showing significant patient response, positions Gamifant as a critical therapeutic option, addressing unmet medical needs and potentially improving patient outcomes in this severe condition.

The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK350.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.

Sobi AGM Approves Key Resolutions and Growth Initiatives

At the Annual General Meeting held on May 8, 2025, Swedish Orphan Biovitrum AB (Sobi) shareholders approved several key resolutions. These included the adoption of financial statements, re-election of board members, and the implementation of long-term incentive programs. The AGM also authorized the board to issue new shares and convertible bonds, enhancing Sobi’s capacity for future growth and strategic initiatives.